Media coverage about Accuray (NASDAQ:ARAY) has trended somewhat positive on Friday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Accuray earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 47.0140968481904 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern’s scoring:
- Global Linear Accelerators for Radiation Market Insights by 2023: Elekta, ACCURAY, Siemens and Varian Medical … (dailyassessment.com)
- Wining Three Stocks: Accuray Incorporated (NASDAQ:ARAY), Great Panther Silver Limited (NYSE:GPL), Senomyx, Inc … (thestreetpoint.com)
- Global Linear Accelerators for Radiation Market Analysis 2018 – Siemens, ACCURAY, Elekta and Varian Medical … (consumerelectronics24.com)
- Radiotherapy Device Market 2018 – Varian Medical Systems, Elekta AB, Accuray, Inc., CR Bard, Inc., IBA Ion Beam … (globaltopkeyplayers.com)
- 50 days simple moving average (SMA50) in the Limelight Accuray Incorporated (NASDAQ:ARAY), Kayne Anderson … (stocksnewspoint.com)
Shares of Accuray opened at $4.90 on Friday, according to MarketBeat.com. Accuray has a 1 year low of $4.72 and a 1 year high of $4.77. The stock has a market cap of $411.06 million, a PE ratio of -13.61 and a beta of 1.75. The company has a debt-to-equity ratio of 3.00, a quick ratio of 0.97 and a current ratio of 1.62.
A number of analysts have recently issued reports on ARAY shares. BidaskClub lowered Accuray from a “buy” rating to a “hold” rating in a research report on Thursday, February 8th. Royal Bank of Canada set a $6.00 target price on Accuray and gave the stock a “hold” rating in a research report on Tuesday, April 10th. Finally, Zacks Investment Research lowered Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, March 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $7.21.
In related news, CEO Joshua Levine sold 8,675 shares of Accuray stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $4.65, for a total value of $40,338.75. Following the completion of the transaction, the chief executive officer now directly owns 1,426,753 shares in the company, valued at $6,634,401.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 14,257 shares of company stock valued at $66,295 over the last quarter. Insiders own 3.90% of the company’s stock.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.